Seres Therapeutics Reports SER-155 Phase 1b Results Published in Nature Medicine
The peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections among allogeneic hematopoietic cell transplantation recipients.
Related stories
Nasdaq single-stock trading halt continues, symbol not given — reason not given (10:35 AM ET)
Nasdaq kept trading halted in a single listed security (reason not given) at 10:35 AM ET.
M impact | EQUITY | Nov 03, 2026, 03:52 PM UTC
S&P 500 and Nasdaq Edge Higher Ahead of Midterm Results; Apple Falls 2%
US stocks rose as crude oil prices fell ahead of midterm election results. Apple shares dropped 2% after its earnings failed to impress investors.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Pfizer lifts full-year guidance after robust third-quarter results
Pfizer reported third-quarter revenue of $16.6 billion, largely unchanged from a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
M impact | EQUITY | Nov 03, 2026, 03:38 PM UTC
Meta Platforms Reportedly Targets Up to $25 Billion Bond Sale
Meta Platforms has reportedly launched an investment-grade bond sale, targeting up to $25 billion.
M impact | EQUITY | Nov 03, 2026, 03:37 PM UTC
Apollo Reports $53 Billion in Third-Quarter Inflows, AUM Reaches $1.07 Trillion
Apollo Global Management said demand for private credit, insurance and other alternative investments helped drive record fee-related earnings.
M impact | EQUITY | Nov 03, 2026, 03:36 PM UTC
Apple CEO Says Timing of iPhone Supply-Demand Balance Is Uncertain
Apple’s CEO said the company cannot predict when iPhone supply and demand will balance.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC